Does TEVA PHARMACEUTICAL INDUSTRIES LIMITED have an economic moat?

Based on its FY2025 SEC filings, the Moat Index scores TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVA) 47.8 out of 100 — a Shallow moat. The four filters behind that score (each 0–100): pricing power 79, returns on capital 7, balance-sheet safety 56, capital discipline 55.

Is TEVA stock trading below its intrinsic value?

Against a deliberately conservative owner-earnings model (9% discount rate, 4% assumed growth, capped at 4%), estimated intrinsic value is $1.06 per share versus a recent price of $32.03 — 2909% above value. This is an educational estimate computed from primary SEC filings, not investment advice.

How has TEVA's Moat Score changed over time?

The record logs 3 readings since Jul 17, 2026; the latest reads 47.8 out of 100 (shallow moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.

The Moat Index

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

TEVA · Healthcare · $36.8B mkt cap · FY2025 filings · Shallow moat ·

Doesn't clear the bar

Shallow moat

The four filters

Pricing power79

Median gross margin 48.0% over 10y, very stable.

Returns on capital7

Median ROIC -4.3%, above the 9% hurdle in 20% of years.

Balance-sheet safety56

Net cash position — no leverage risk.

Capital discipline55

Owner earnings +8.1%/yr, share count growing (dilution).

Margin of safety

Above valueOn sale

2909% above value

Owner earnings (normalized): $68.0M
Est. intrinsic value / share: $1.06
Recent price: $32.03
Discount to value: 2909% above value

Conservative model: 9% discount rate, 4% assumed growth (capped at 4%), maintenance capex ≈ min(capex, D&A).

12 years of fundamentals

The business, in plain English

TEVA PHARMACEUTICAL INDUSTRIES LIMITED booked $17.3B of revenue in FY2025 in the Healthcare sector and kept 51.8% of it as gross profit — a solid-margin business by that measure. After every other cost, 8.2% of each revenue dollar reached the bottom line.

Across the filed record, revenue shrank from $19.7B (FY2015) to $17.3B (FY2025) — about −1.3% a year compounded over 10 years.

It earned 34.9% on invested capital in FY2025, with a median of −2.4% across 11 filed years. The Returns on Capital filter above scores it 7/100.

The balance sheet carried $1.8B of total debt in FY2025 against $1.9B of owner earnings — roughly 1.0 years of owner earnings to retire it all. Balance-Sheet Safety scores it 56/100.

The share count rose 5.5% between FY2018 and FY2025 — existing owners have been diluted over the record. Capital Discipline scores it 55/100.

Put together: Pricing Power is the strongest of the four filters (79/100) and Returns on Capital the weakest (7/100), which is how TEVA lands at 48/100 — a Shallow moat.

This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.

RevenueSales, as filed$17.3B FY2025

Gross marginRevenue kept after cost of goods51.8% FY2025

Return on invested capitalOperating profit on the capital employed34.9% FY2025

Owner earningsCash an owner could take out$1.9B FY2025

Gaps in a line mean that item isn’t in TEVA’s filings for that year — the series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.

Moat Score history

Moat Score over timeLast scored reading of each day, on the 0–100 scale47.8 / 100

Score history begins Jul 17, 2026 — the record builds from here and can’t be backfilled.

Tier changesSame-methodology crossings of the Wide / Narrow / Shallow bars

None yet — TEVA has read Shallow moat for every logged capture since Jul 17, 2026.

Scores are logged append-only and never overwritten — this record can’t be backfilled, which is exactly why it’s worth keeping.

Healthcare context

#133 of 440 scored Healthcare companies, ranked by Moat Score.

Nearest peers by Moat Score

#131PAHC Phibro Animal Health Corporation47.9 out of 100, Shallow moatShallow moat
#132ONC BEONE MEDICINES LTD.47.9 out of 100, Shallow moatShallow moat
#134ROP ROPER TECHNOLOGIES INC47.5 out of 100, Shallow moatShallow moat
#135TGTX TG THERAPEUTICS, INC.47.5 out of 100, Shallow moatShallow moat

Compare TEVA with its nearest peers →All Healthcare companies on the Index →

Common questions about TEVA

Does TEVA PHARMACEUTICAL INDUSTRIES LIMITED have an economic moat?: Based on its FY2025 SEC filings, the Moat Index scores TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVA) 47.8 out of 100 — a Shallow moat. The four filters behind that score (each 0–100): pricing power 79, returns on capital 7, balance-sheet safety 56, capital discipline 55.
Is TEVA stock trading below its intrinsic value?: Against a deliberately conservative owner-earnings model (9% discount rate, 4% assumed growth, capped at 4%), estimated intrinsic value is $1.06 per share versus a recent price of $32.03 — 2909% above value. This is an educational estimate computed from primary SEC filings, not investment advice.
How has TEVA's Moat Score changed over time?: The record logs 3 readings since Jul 17, 2026; the latest reads 47.8 out of 100 (shallow moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.

Embed this score on your site

One iframe, no script. The badge shows TEVA’s live Moat Score, updates itself as new filings are scored, and links back here. How it works.

<iframe
  src="https://buylikebuffett.com/embed/TEVA"
  width="340" height="150" style="border:0"
  title="TEVA Moat Score — The Moat Index"
  loading="lazy"></iframe>

Scored from primary SEC filings via the public methodology. Educational only — not a recommendation to buy or sell TEVA. See the disclaimer.